What Should Neil Woodford Do With Allied Minds plc, Drax Group Plc & Rolls-Royce Holding plc Right Now?

Allied Minds plc (LON:ALM) is a stronger bet than Drax Group Plc (LON:DRX) and Rolls-Royce Holding plc (LON:RR) at this level, argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In a recent update on his fund’s performance, Neil Woodford showed where he has made and lost money in the 12 months to the end of June. 

Allied Minds (LSE: ALM) is one of the best performers in his portfolio, but Rolls-Royce (LSE: RR) and Drax (LSE: DRX) were a drag. 

What’s next for these three companies is less obvious than it may seem at first sight. 

Why Allied Minds? 

Allied Minds had an average weight of 2.95% in Woodford’s portfolio — a percentage that is almost in the middle of the highest and the lowest exposure to any stock in his fund. It signals that if you invest in it, you’d do well to be careful with regard to the amount of stock you end up owning. 

Its performance contribution, at 3.21%, tops the ranking by some distance, which reflects a higher level of risk compared to that of several other holdings in Woodford’s portfolio. 

One obvious question now is whether the shares of Allied Minds have lost their sparkle?

Consider that its equity valuation is up 114% in the last year of trade, but its shares now change hands around their one-year median of 473p, for an implied forward valuation of 123 times based on the group’s market cap of £1bn divided by forward revenues of £8.3m — trailing revenues stood just below £8m. 

You’d expect a much higher growth rate for revenues or earnings or both to bet on its stock. 

After all, the biggest highlight of 2014 was its IPO, which was priced at 190p, for an implied market value of about £400m. It raised proceeds of $155m. Based on its funding needs, Allied Minds should be safe for a couple of years at least, in my view. 

No other key financial metric is available, though, and that’s because the company is at an early stage of maturity. A truly attractive feature is the sector where Allied Minds operates, given that it focuses on the commercialisation of scientific discoveries from universities and federal government institutions in the US.

While I’m really tempted to add its stock to my portfolio at this price, I need more evidence that the business can generate earnings and positive cash flows before committing to it for the long term. 

Rolls & Drax: What Do They Have In Common? 

The shares of both companies have fallen off a cliff in recent weeks, yet I think that Rolls-Royce offers more value than Drax at present time. 

Regulatory risk is a significant hurdle for Drax because the UK government is amending its green policy, withdrawing subsidies to the energy sector.

In Woodford’s portfolio, Drax had an average weight of 1.55% and recorded a performance contribution of -0.98% — it’s the worst performer ahead of GlaxoSmithKline (-0.91%), the second-largest holding in his portfolio, with an average weight of 6.49%. 

Drax’s valuation has not recoverd since its 30% drop on 8 July, when the group announced that the government had decided to “remove the Climate Change Levy (CCL) exemption for renewable electricity generated after 1 August 2015″, which prompted lower guidance for cash flows and earnings. 

The power producer has begun a strategic review of its operations, gauging its “long-term options” — in these situations, a takeover becomes the most likely outcome.

If you are tempted to bet on that, however, consider that its shares trade on forward earnings multiples north of 30x, and that Drax would cost up to £1.5bn or more, which isn’t exactly small change in this market, although it could draw the attention of infrastructure funds. 

In fairness, I’d rather bet on Rolls-Royce, which is not a bargain but whose shares trade on lower forward net earnings multiples in the mid-teens.

Rolls Rallies

With an average weight of 2.96% and a performance contribution of -0.57%, Rolls has been a rather disappointing investment for Woodford, but the tide may be turning.

Only a few weeks after a profit warning pushed down its stock close to its lowest level for almost four years, Rolls has rallied (+16% since 27 July) on the back of several rumours according to which activist investors could have a strategy to turn around the ailing engine maker. 

Rolls-Royce Holdings PLC on Monday said its top leaders met with ValueAct Capital Management after the activist investor raised its stake to more than 5% in the British aircraft-engine maker,” Dow Jones  reported on Monday.

That’s all we know, and it’s encouraging — but there are plenty of risks that could still sink the valuation of Rolls.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended shares in GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »